Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 18Metastatic Castration-resistant Prostate Cancer 3Prostatic Neoplasms, Castration-Resistant 2Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Breast Neoplasms 1Abiraterone Acetate 1

Interventions

enzalutamide 2Prednisone 2Abiraterone Acetate 2tasquinimod 1sabizabulin 1niraparib 1darolutamide 1atezolizumab 1abiraterone 1Radiosurgery 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT03748641 2026-06-05

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04844749 2024-02-05

VERACITY

Veru Inc.

Phase 3 Terminated
105 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡